MoneyWorks4Me

Sanofi India - Quaterly Results

14 May 2025 Evaluate
The total revenue for the quarter ended March 2025 remained nearly unchanged at Rs. 5359.00 millions.Profit after tax for the quarter ended March 2025 reported a huge growth of 65.97% to Rs. 1195.00  millions from Rs. 720.00 millions.Operating profit surged to 1752.00 millions from the corresponding previous quarter of 1406.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202412 202312 % Var
Sales 5359.00 5108.00 4.91 5359.00 5108.00 4.91 20132.00 19961.00 0.86
Other Income 33.00 35.00 -5.71 33.00 35.00 -5.71 165.00 612.00 -73.04
PBIDT 1752.00 1406.00 24.61 1752.00 1406.00 24.61 5073.00 5489.00 -7.58
Interest 3.00 3.00 0.00 3.00 3.00 0.00 15.00 17.00 -11.76
PBDT 1749.00 1136.00 53.96 1749.00 1136.00 53.96 4681.00 5650.00 -17.15
Depreciation 96.00 91.00 5.49 96.00 91.00 5.49 367.00 365.00 0.55
PBT 1653.00 1045.00 58.18 1653.00 1045.00 58.18 4314.00 5285.00 -18.37
TAX 458.00 325.00 40.92 458.00 325.00 40.92 1177.00 1639.00 -28.19
Deferred Tax 1.00 -72.00 -101.39 1.00 -72.00 -101.39 -81.00 5.00 -1720.00
PAT 1195.00 720.00 65.97 1195.00 720.00 65.97 3137.00 3646.00 -13.96
Equity 230.00 230.00 0.00 230.00 230.00 0.00 230.00 230.00 0.00
PBIDTM(%) 32.69 27.53 18.77 32.69 27.53 18.77 25.20 27.50 -8.36
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..